[治疗骨质疏松的药物。]

Clinical calcium Pub Date : 2018-01-01 DOI:CliCa1801114116

Seiji Fukumoto

{"title":"[治疗骨质疏松的药物。]","authors":"Seiji Fukumoto","doi":"CliCa1801114116","DOIUrl":null,"url":null,"abstract":"Many important results concerning several drugs for osteoporosis have been presented in ASBMR 2017 meeting. Longer use of denosumab for up to 10 years was shown to induce lower risk of fractures. In addition, antiresorptives were shown to be useful after abaloparatide or romosozumab. Now that several important drugs have been already developed for osteoporosis, research and drug development for other musculoskeletal organs than bone are necessary.","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"28 1","pages":"114-116"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Drugs for osteoporosis.]\",\"authors\":\"Seiji Fukumoto\",\"doi\":\"CliCa1801114116\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Many important results concerning several drugs for osteoporosis have been presented in ASBMR 2017 meeting. Longer use of denosumab for up to 10 years was shown to induce lower risk of fractures. In addition, antiresorptives were shown to be useful after abaloparatide or romosozumab. Now that several important drugs have been already developed for osteoporosis, research and drug development for other musculoskeletal organs than bone are necessary.\",\"PeriodicalId\":10389,\"journal\":{\"name\":\"Clinical calcium\",\"volume\":\"28 1\",\"pages\":\"114-116\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical calcium\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/CliCa1801114116\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical calcium","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/CliCa1801114116","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

ASBMR 2017会议上提出了许多关于几种骨质疏松症药物的重要结果。长期使用denosumab达10年可降低骨折风险。此外，抗吸收剂在阿巴洛帕肽或罗莫索单抗之后也被证明是有用的。现在已经开发出几种治疗骨质疏松症的重要药物，研究和开发针对骨骼以外的其他肌肉骨骼器官的药物是必要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[Drugs for osteoporosis.]

Many important results concerning several drugs for osteoporosis have been presented in ASBMR 2017 meeting. Longer use of denosumab for up to 10 years was shown to induce lower risk of fractures. In addition, antiresorptives were shown to be useful after abaloparatide or romosozumab. Now that several important drugs have been already developed for osteoporosis, research and drug development for other musculoskeletal organs than bone are necessary.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical calcium

自引率

0.00%

发文量